Baxter International has entered into a definitive agreement to acquire Prism Pharmaceuticals. The purchase includes Prism’s Nexterone product portfolio and consists of a $170 million upfront payment at closing and as much as $168 million in future sales milestones, for a potential total of $338 million. Nexterone (amiodarone HCl) is an antiarrhythmic agent approved by the FDA for multiple presentations, including ready-to-use premixed intravenous (IV) bag formulations, vials, and a pre-filled s...